Mihirkumar P. Parmar
Mihirkumar P. Parmar has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Saleh Mohammed
Faridpur Medical College
4 shared publications Vishal Venugopal
Bhaarath Medical College and Hospital, Chennai, India
4 shared publications- Lyluma Ishfaq
Government medical college, Srinagar, Directorate of health services Kashmir Srinagar, J&k , India
2 shared publications - Narendranath Reddy Ganampet
Department of Internal Medicine, Kamineni Academy of Medical Sciences and Research Centre, Telangana, India
2 shared publications - Navya Pillikunte Doddareddy
Bangalore Medical College and Research Institute, Bangalore, India
2 shared publications Sai Nimmagadda
Gandhi Medical College
2 shared publications
Latest Publications
- Open Access
- 24 November 2025
- Published by Wiley in Clinical Case Reports
- Vol. 13 (12)
Rapidly Progressive Multiple System Atrophy—Cerebellar Type in a 52‐Year‐Old Woman: Diagnostic Challenges in a Resource‐Limited Setting
Multiple system atrophy (MSA) is a progressive adult‐onset neurodegenerative disorder that manifests as a variable combination of cerebellar, parkinsonian, and autonomic dysfunctions. We report a case of a 52‐year‐old woman who presented with rapidly progressive gait ataxia, dysarthria, orthostatic hypotension, and urinary urgency. MRI of the brain demonstrated pontocerebellar atrophy with the characteristic “hot cross bun” sign, supporting a diagnosis of Multiple System Atrophy–cerebellar type (MSA‐C). Despite receiving levodopa and supportive therapy, the symptoms progressed over 8 months, highlighting the unusually rapid disease course. This case highlights the diagnostic value of targeted clinical assessment and MRI when advanced confirmatory tests are inaccessible, underscoring the importance of early recognition and multidisciplinary symptom management in resource‐constrained settings.
- 24 November 2025
- Published by Wiley in Clinical Case Reports
- Vol. 13 (12)
Open AccessRapidly Progressive Multiple System Atrophy—Cerebellar Type in a 52‐Year‐Old Woman: Diagnostic Challenges in a Resource‐Limited Setting
Multiple system atrophy (MSA) is a progressive adult‐onset neurodegenerative disorder that manifests as a variable combination of cerebellar, parkinsonian, and autonomic dysfunctions. We report a case of a 52‐year‐old woman who presented with rapidly progressive gait ataxia, dysarthria, orthostatic hypotension, and urinary urgency. MRI of the brain demonstrated pontocerebellar atrophy with the characteristic “hot cross bun” sign, supporting a diagnosis of Multiple System Atrophy–cerebellar type (MSA‐C). Despite receiving levodopa and supportive therapy, the symptoms progressed over 8 months, highlighting the unusually rapid disease course. This case highlights the diagnostic value of targeted clinical assessment and MRI when advanced confirmatory tests are inaccessible, underscoring the importance of early recognition and multidisciplinary symptom management in resource‐constrained settings.
- Open Access
- 12 November 2025
- Published by Wiley in Clinical Case Reports
- Vol. 13 (11) , e71384
Moyamoya Disease in an Eight‐Year‐Old Female Child—A Case Report
An eight‐year‐old girl presented with a first episode of focal seizure and transient loss of consciousness. Brain MRI revealed a large subacute infarct in the left fronto‐parieto‐temporal region, and MR angiography showed bilateral supraclinoid internal carotid and proximal posterior cerebral artery narrowing with extensive basal collateral formation, consistent with Moyamoya disease. The absence of aneurysm or arteriovenous malformation excluded other vascular anomalies. She was managed with hypertonic saline, intravenous antibiotics, and antiplatelet therapy, followed by stabilization and referral for surgical revascularization. This case underscores the importance of maintaining a high index of suspicion for Moyamoya disease in children presenting with new‐onset seizures or stroke‐like episodes. Early neuroimaging and multidisciplinary management are essential to prevent further ischemic injury and optimize neurological outcomes.
- 12 November 2025
- Published by Wiley in Clinical Case Reports
- Vol. 13 (11) , e71384
Open AccessMoyamoya Disease in an Eight‐Year‐Old Female Child—A Case Report
An eight‐year‐old girl presented with a first episode of focal seizure and transient loss of consciousness. Brain MRI revealed a large subacute infarct in the left fronto‐parieto‐temporal region, and MR angiography showed bilateral supraclinoid internal carotid and proximal posterior cerebral artery narrowing with extensive basal collateral formation, consistent with Moyamoya disease. The absence of aneurysm or arteriovenous malformation excluded other vascular anomalies. She was managed with hypertonic saline, intravenous antibiotics, and antiplatelet therapy, followed by stabilization and referral for surgical revascularization. This case underscores the importance of maintaining a high index of suspicion for Moyamoya disease in children presenting with new‐onset seizures or stroke‐like episodes. Early neuroimaging and multidisciplinary management are essential to prevent further ischemic injury and optimize neurological outcomes.
- Open Access
- 30 June 2025
- Published by Wiley
Moyamoya disease in an eight years old female child -- A case report
- 30 June 2025
- Published by Wiley
Open AccessMoyamoya disease in an eight years old female child -- A case report
- Open Access
- 26 June 2025
- Published by Wiley
Case report on rapidly progressive Multiple system atrophy type C
- 26 June 2025
- Published by Wiley
Open AccessCase report on rapidly progressive Multiple system atrophy type C
- Open Access
- 18 November 2023
- Published by Wiley
Hemoptysis secondary to Anomalous Origin of Right Pulmonary Artery from ascending aorta in a young male: A case report
Title: Hemoptysis Secondary to Anomalous Origin of Right Pulmonary Artery from Ascending Aorta in a Young Male: A Case Report
- 18 November 2023
- Published by Wiley
Open AccessHemoptysis secondary to Anomalous Origin of Right Pulmonary Artery from ascending aorta in a young male: A case report
Title: Hemoptysis Secondary to Anomalous Origin of Right Pulmonary Artery from Ascending Aorta in a Young Male: A Case Report
- Open Access
- 25 September 2023
- Published by Springer Nature in Research Square
A Rare Case of Digital Ulceration and Gangrene as an Initial Presentation of Systemic Lupus Erythematosus in a Child
Systemic lupus erythematosus (SLE) is an intricate autoimmune disorder that can manifest a plethora of symptoms. Tissue-binding autoantibodies and intricate immune complexes orchestrate the initial harm to organs and cellular structures. Amid its expansive array of manifestations, dermatological indications, notably digital gangrene and ulcers, are rare occurrences in the context of systemic lupus erythematosus and typically emerge in the advanced stages of the ailment. In this discussion, we present an exceptional case of early-onset digital gangrene and ulcers in a youthful patient grappling with systemic lupus erythematosus. This is a case study of a 7-year-old male who sought medical attention with urticarial rashes over his entire body and face, skin desquamation, and sporadic fever episodes. The preliminary assessment encountered challenges in distinguishing this presentation from acute urticaria. However, subsequent in-depth diagnostic scrutiny and serological analysis substantiated the patient's affliction with SLE. Digital gangrene, ulcers, and vasculitis became evident at the distal portions of the fingers. The diagnosis was conclusively established through clinical and serological methods. The patient exhibited positive results for antinuclear antibodies (ANA), anti-ribonuclear protein (Anti-RNP) antibodies, anti-Smith (Anti-Sm) antibodies, and anti-Sjögren's syndrome-related antigen A (Anti-SS-A) antibodies. This case underscores the pivotal importance of acknowledgment of the rare and severe manifestations of SLE in the realm of medical practice.
- 25 September 2023
- Published by Springer Nature in Research Square
Open AccessA Rare Case of Digital Ulceration and Gangrene as an Initial Presentation of Systemic Lupus Erythematosus in a Child
Systemic lupus erythematosus (SLE) is an intricate autoimmune disorder that can manifest a plethora of symptoms. Tissue-binding autoantibodies and intricate immune complexes orchestrate the initial harm to organs and cellular structures. Amid its expansive array of manifestations, dermatological indications, notably digital gangrene and ulcers, are rare occurrences in the context of systemic lupus erythematosus and typically emerge in the advanced stages of the ailment. In this discussion, we present an exceptional case of early-onset digital gangrene and ulcers in a youthful patient grappling with systemic lupus erythematosus. This is a case study of a 7-year-old male who sought medical attention with urticarial rashes over his entire body and face, skin desquamation, and sporadic fever episodes. The preliminary assessment encountered challenges in distinguishing this presentation from acute urticaria. However, subsequent in-depth diagnostic scrutiny and serological analysis substantiated the patient's affliction with SLE. Digital gangrene, ulcers, and vasculitis became evident at the distal portions of the fingers. The diagnosis was conclusively established through clinical and serological methods. The patient exhibited positive results for antinuclear antibodies (ANA), anti-ribonuclear protein (Anti-RNP) antibodies, anti-Smith (Anti-Sm) antibodies, and anti-Sjögren's syndrome-related antigen A (Anti-SS-A) antibodies. This case underscores the pivotal importance of acknowledgment of the rare and severe manifestations of SLE in the realm of medical practice.
- Open Access
- 22 September 2023
- Published by Springer Nature in Research Square
A Systematic Review on NSAID and Tanezumab efficacy in Chronic Lower Back Pain
Chronic back pain is an ailment that impacts people of all ages and lasts longer than 12 weeks. 7.41% of all Years Lost to Disability (YLD) are associated with low back pain, which makes it the pathology responsible for the most YLD, surpassing other chronic conditions such as Diabetes and Depression. Despite the prevalence of drugs such as nonsteroidal anti-inflammatory drugs (NSAIDs), painkillers, and biologics, the types of drugs administered to individuals differ greatly. We collected data from the PubMed database of the PubMed database, National Library of Medicine (NIH), and Google Scholar. Randomized controlled trials (RCTs) that explicitly evaluate the effectiveness of various NSAIDs in adult patients with chronic back pain were selected for this study. After an exhaustive search and examination of numerous publications, only 8 articles met the inclusion criteria. In recent studies that included NSAIDs, they were among the most frequently prescribed medications for the treatment of chronic low back pain. In comparison to placebo, selective COX-II inhibitors such as celecoxib and etoricoxib were found to be efficacious, while valdecoxib was associated with serious side effects. In addition to reducing back pain, COX-II inhibitors with a preference for COX-II, such as aceclofenac and diclofenac, were associated with gastrointestinal side effects. Despite the risk of joint degeneration and accelerated osteoarthritis, intravenous tanezumab may be superior to naproxen and placebo in treating chronic low back pain.
- 22 September 2023
- Published by Springer Nature in Research Square
Open AccessA Systematic Review on NSAID and Tanezumab efficacy in Chronic Lower Back Pain
Chronic back pain is an ailment that impacts people of all ages and lasts longer than 12 weeks. 7.41% of all Years Lost to Disability (YLD) are associated with low back pain, which makes it the pathology responsible for the most YLD, surpassing other chronic conditions such as Diabetes and Depression. Despite the prevalence of drugs such as nonsteroidal anti-inflammatory drugs (NSAIDs), painkillers, and biologics, the types of drugs administered to individuals differ greatly. We collected data from the PubMed database of the PubMed database, National Library of Medicine (NIH), and Google Scholar. Randomized controlled trials (RCTs) that explicitly evaluate the effectiveness of various NSAIDs in adult patients with chronic back pain were selected for this study. After an exhaustive search and examination of numerous publications, only 8 articles met the inclusion criteria. In recent studies that included NSAIDs, they were among the most frequently prescribed medications for the treatment of chronic low back pain. In comparison to placebo, selective COX-II inhibitors such as celecoxib and etoricoxib were found to be efficacious, while valdecoxib was associated with serious side effects. In addition to reducing back pain, COX-II inhibitors with a preference for COX-II, such as aceclofenac and diclofenac, were associated with gastrointestinal side effects. Despite the risk of joint degeneration and accelerated osteoarthritis, intravenous tanezumab may be superior to naproxen and placebo in treating chronic low back pain.
- Open Access
- 21 September 2023
- Published by Springer Nature in Research Square
Impact of Proton Pump Inhibitors on Kidney Function and Chronic Kidney Disease Progression: A Systematic Review
Aim: The aim of this systematic review is to comprehensively assess and analyze the impact of proton pump inhibitors on kidney function and their potential role in the progression of chronic kidney disease. Through a meticulous examination of available literature, we aim to provide a clear understanding of the relationship between proton pump inhibitor use and kidney health, shedding light on potential risks, benefits, and contributing factors. Ultimately, this research aims to inform healthcare professionals and patients alike about the implications of proton pump inhibitors on kidney function, facilitate informed medical decisions, and improve patient care. Methods: We used the following medical subject headings (MeSH) terms with keywords like "irritable bowel syndrome" and "kidney injury" to gather data from the National Library of Medicine (PubMed), PubMed Central (PMC), and Google Scholar. Articles from the last 10 years, 2013 to 2023, were gathered for this systematic review. Results: The results indicate a complex relationship between proton pump inhibitors and kidney function, as well as the progression of chronic kidney disease. Conclusion: In the end, this systematic review shows that there is a link between long-term use of proton pump inhibitors and a higher risk of kidney problems. Patients and healthcare providers should weigh the benefits of proton pump inhibitor therapy against potential risks, especially in individuals with pre-existing kidney conditions, and consider alternative treatment options when appropriate. Regular monitoring of kidney function in proton pump inhibitor users may also be advisable to ensure early detection and management of any adverse effects.
- 21 September 2023
- Published by Springer Nature in Research Square
Open AccessImpact of Proton Pump Inhibitors on Kidney Function and Chronic Kidney Disease Progression: A Systematic Review
Aim: The aim of this systematic review is to comprehensively assess and analyze the impact of proton pump inhibitors on kidney function and their potential role in the progression of chronic kidney disease. Through a meticulous examination of available literature, we aim to provide a clear understanding of the relationship between proton pump inhibitor use and kidney health, shedding light on potential risks, benefits, and contributing factors. Ultimately, this research aims to inform healthcare professionals and patients alike about the implications of proton pump inhibitors on kidney function, facilitate informed medical decisions, and improve patient care. Methods: We used the following medical subject headings (MeSH) terms with keywords like "irritable bowel syndrome" and "kidney injury" to gather data from the National Library of Medicine (PubMed), PubMed Central (PMC), and Google Scholar. Articles from the last 10 years, 2013 to 2023, were gathered for this systematic review. Results: The results indicate a complex relationship between proton pump inhibitors and kidney function, as well as the progression of chronic kidney disease. Conclusion: In the end, this systematic review shows that there is a link between long-term use of proton pump inhibitors and a higher risk of kidney problems. Patients and healthcare providers should weigh the benefits of proton pump inhibitor therapy against potential risks, especially in individuals with pre-existing kidney conditions, and consider alternative treatment options when appropriate. Regular monitoring of kidney function in proton pump inhibitor users may also be advisable to ensure early detection and management of any adverse effects.
- Open Access
- 21 September 2023
- Published by Springer Nature in Research Square
Long-Term Effects of Treatment Modalities on Metabolic Health, Fertility Outcomes, and Cardiovascular Risks in Lean Women with Polycystic Ovary Syndrome (PCOS): A Systematic Review
Oligomenorrhea with different degrees of follicular and adrenal hyperandrogenism are the hallmarks of the condition of polycystic ovary syndrome (PCOS). For some of the women in their reproductive years, this endocrine illness is incredibly prevalent and comprises a variety of disorders. There are a set of symptoms, such as hirsutism, acne, and insulin resistance, for identifying the characteristics of PCOS. Various treatment modalities have been opted for over the years for the treatment and management of this condition, among which metformin and flutamide are the most prevalent, along with lifestyle modifications as prevalent recommendations to patients. Weight management for obese patients is the most challenging aspect of PCOS management. Still, similar findings are found in women with lean physiology or a normal BMI, indicating that PCOS symptoms prevail and occur irrespective of the BMI, but obese or overweight women face more problems. We determined the long-term effects of treatment modalities on PCOS symptoms and their improvement. Metformin was reported to primarily increase the blood levels of glucose as well as BMI. Blood pressure was also maintained among various researchers, and DHEAS levels were also altered along with serum sex hormone-binding globulin in the plasma of patients undergoing treatments specific for PCOS patients with a normal BMI or lean PCOS. Further studies with more extensive parameters being employed need to be conducted for the determination of the exact mechanism and cause of the disease to ease the treatment process.
- 21 September 2023
- Published by Springer Nature in Research Square
Open AccessLong-Term Effects of Treatment Modalities on Metabolic Health, Fertility Outcomes, and Cardiovascular Risks in Lean Women with Polycystic Ovary Syndrome (PCOS): A Systematic Review
Oligomenorrhea with different degrees of follicular and adrenal hyperandrogenism are the hallmarks of the condition of polycystic ovary syndrome (PCOS). For some of the women in their reproductive years, this endocrine illness is incredibly prevalent and comprises a variety of disorders. There are a set of symptoms, such as hirsutism, acne, and insulin resistance, for identifying the characteristics of PCOS. Various treatment modalities have been opted for over the years for the treatment and management of this condition, among which metformin and flutamide are the most prevalent, along with lifestyle modifications as prevalent recommendations to patients. Weight management for obese patients is the most challenging aspect of PCOS management. Still, similar findings are found in women with lean physiology or a normal BMI, indicating that PCOS symptoms prevail and occur irrespective of the BMI, but obese or overweight women face more problems. We determined the long-term effects of treatment modalities on PCOS symptoms and their improvement. Metformin was reported to primarily increase the blood levels of glucose as well as BMI. Blood pressure was also maintained among various researchers, and DHEAS levels were also altered along with serum sex hormone-binding globulin in the plasma of patients undergoing treatments specific for PCOS patients with a normal BMI or lean PCOS. Further studies with more extensive parameters being employed need to be conducted for the determination of the exact mechanism and cause of the disease to ease the treatment process.
- Open Access
- 19 September 2023
- Published by Springer Nature in Research Square
Genetic Variants Affecting Insulin Signaling Pathways and Risk of Diabetes: A Comprehensive Systematic Review
Purpose The complicated condition known as type 2 diabetes mellitus (T2DM) has a diverse genetic and environment-related cause. MIM125853 is among the heterogeneous diseases that can also be characterized as a multifactorial disorder of glucose metabolism with genetic susceptibility of an anomaly in the insulin pathway. We conducted the review with aim to assess the genetic variants affecting the insulin pathway as well as evaluate the risk of diabetes in association with genetic variants. Methods We used literature of 13 researches that met the inclusion criteria after the process of selection and analyzation. Our analysis included 59,593 participants in total with a gender distribution of 48% males (n = 24,591) and 52% females (n = 35,002). Result Gene variants such as PPARG, SLC30A8, KCNJ11, TCF7L2 and many others plays a pivotal role in the development of type-II diabetes as well as optimal functioning of insulin metabolic pathway for glucose metabolism and distribution with circulation. Conclusion KCNJ11 regulates insulin release in collaboration with other genes including ABCC8, KAPN10, IRS1 and TCF7L2. Reduced mutual expression of these kinds of genes could contribute to DM susceptibility. However, it is still unknown how precisely the combination of these genes’ functions in the control of insulin secretion.
- 19 September 2023
- Published by Springer Nature in Research Square
Open AccessGenetic Variants Affecting Insulin Signaling Pathways and Risk of Diabetes: A Comprehensive Systematic Review
Purpose The complicated condition known as type 2 diabetes mellitus (T2DM) has a diverse genetic and environment-related cause. MIM125853 is among the heterogeneous diseases that can also be characterized as a multifactorial disorder of glucose metabolism with genetic susceptibility of an anomaly in the insulin pathway. We conducted the review with aim to assess the genetic variants affecting the insulin pathway as well as evaluate the risk of diabetes in association with genetic variants. Methods We used literature of 13 researches that met the inclusion criteria after the process of selection and analyzation. Our analysis included 59,593 participants in total with a gender distribution of 48% males (n = 24,591) and 52% females (n = 35,002). Result Gene variants such as PPARG, SLC30A8, KCNJ11, TCF7L2 and many others plays a pivotal role in the development of type-II diabetes as well as optimal functioning of insulin metabolic pathway for glucose metabolism and distribution with circulation. Conclusion KCNJ11 regulates insulin release in collaboration with other genes including ABCC8, KAPN10, IRS1 and TCF7L2. Reduced mutual expression of these kinds of genes could contribute to DM susceptibility. However, it is still unknown how precisely the combination of these genes’ functions in the control of insulin secretion.